Long Term Outcomes of Vivity Intra Ocular Lens(IOL) Versus Control
NCT ID: NCT04561570
Last Updated: 2023-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
32 participants
OBSERVATIONAL
2020-09-17
2021-04-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Corrected VA With Long-Term Follow-Up After AcrySof® Intraocular Lens (IOL) Implantation
NCT02450799
Clinical Investigation of the AcrySof IQ Vivity Extended Vision Intraocular Lens (IOL)
NCT04098367
Visual Acuity Outcome Differences Between the Alcon Vivity Toric IOL and RxSight LAL+
NCT06574646
Evaluation of AcrySof IQ Vivity Extended Vision Intraocular Lenses
NCT06541795
Vivity IOL: Emmetropia Compared to Monovision.
NCT05464732
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study Group: Vivity ACRYSOF IQ IOL
Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
Vivity ACRYSOF IQ IOL Group
Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
Control Group: ACRYSOF IQ IOL
Control Group: Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
ACRYSOF IQ IOL Control Group
Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vivity ACRYSOF IQ IOL Group
Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
ACRYSOF IQ IOL Control Group
Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
The Eye Associates
OTHER
Eye Care Specialists
UNKNOWN
NewsomeEye
UNKNOWN
John Berdahl, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Berdahl, MD
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vance Thompson Vision
Sioux Falls, South Dakota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
The REVIVE Study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.